Explore

Companies

Drugs

About·Data Management·Terms·Privacy

Stay informed

© 2026 VivoSeq. All rights reserved.

Bayer

OTC:BAYRYPharma

Leverkusen, North Rhine-Westphalia, Germany · Est. 1863 · 100,000 employees

Bayer is a multinational pharmaceutical and life sciences company focused on human and animal health, crop science, and consumer health products.

54

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

67

Indications↗

Distinct diseases across all programs

1,622

Clinical Trials↗

All sponsored trials (all statuses)

69

Orange Book Patents

Across 14 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

54 drugs in development

Approved6

Phase 312

Phase 220

Phase 117

Preclinical17

By Therapeutic Area

top 6

Oncology

2635%

Nephrology

811%

Cardiovascular

68%

Hematology

57%

Neurology

45%

Rare Disease

45%

R&D Momentum

83/100

Pipeline Velocity

61/100

Trial Completion Rate

92/100

Pipeline Concentration

17/100

Pipeline Freshness

75/100

Strategic Signals

↗Active in Respiratory but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

A Parallel-group Treatment, Phase 2, Double-blind, Three-arm Study to Assess Efficacy and Safety of Finerenone Plus Empagliflozin Compared With Either Finerenone or Empagliflozin Alone in Participants With Chronic Kidney Disease and Type 2 Diabetes.

A Natural History Study of Treated Parkinson's Disease Patients Experiencing Motor Complications

Active, not recruiting

Special Drug Use Investigation of Rivaroxaban in Pediatric Patients With Congenital Heart Disease (CHD) Who Had Undergone the Fontan Procedure

A Multicenter, Open Label, Non-randomized First-in-human Phase 1 Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Activity of BAY 3547926 Alone, and in Combination, in Participants With Advanced Hepatocellular Carcinoma (HCC)

Active, not recruiting

A Double-blind, Randomized, Placebo-controlled Multicenter Study to Investigate Efficacy and Safety of Elinzanetant for the Treatment of Vasomotor Symptoms Induced by Adjuvant Endocrine Therapy, Over 52 Weeks and Optionally for an Additional up to 3.5 Years in Women With Hormone-receptor Positive Breast Cancer:

A Phase 2 Open-label Basket Study to Evaluate the Efficacy and Safety of Orally Administered Reversible Tyrosine Kinase Inhibitor BAY 2927088 in Participants With Metastatic or Unresectable Solid Tumors With HER2-activating Mutations

Active, not recruiting

SepThrom: Exploring the Relationship Between Sepsis, VTE and DIC in RWD.

PrOspective Non-interventional Study in Patients With Locally Advanced or Metastatic TRK Fusion Cancer Treated With Larotrectinib

Special Drug Use Investigation for Larotrectinib

Active, not recruiting

An Open-label, Phase 1, First-in-human, Dose Escalation and Expansion Study to Evaluate the Safety, Tolerability, Maximum Tolerated or Administered Dose, Pharmacokinetics, Pharmacodynamics, and Tumor Response Profile of the Diacylglycerol Kinase Zeta Inhibitor (DGKzi) BAY 2965501 as Monotherapy, and in Combination, in Participants With Advanced Solid Tumors

Active, not recruiting

A Randomized, Double-blind, Placebo-controlled Phase 3 Study of Darolutamide Plus Androgen Deprivation Therapy (ADT) Compared With Placebo Plus ADT in Patients With High-risk Biochemical Recurrence (BCR) of Prostate Cancer

Details

Company Info

Company Overview

$55.0B

Mkt Cap

$46.0B

Revenue

—

Cash

CEOBill Anderson

Founded1863

Employees100,000

HQLeverkusen, North Rhine-Westphalia, Germany

ExchangeOTC:BAYRY

Websitebayer.com

LinkedInCompany Page

Therapeutic Focus

OncologyMetabolic & EndocrineOtherNephrologyInfectious DiseaseRespiratoryCardiovascularGastroenterologyOphthalmologyNeurologyImmunologyRare DiseaseHematologyDermatologyMusculoskeletalPsychiatry

Patent Expirations

36 patent groups across drugs · Source: FDA Orange Book

DrugExpires

LynkuetSep 15, 2026 AdempasDec 4, 2026 LevitraJul 23, 2027 NexavarDec 24, 2027 NexavarSep 10, 2028 LevitraDec 23, 2028 Cipro4 patentsApr 21, 2029 Avelox2 patentsMay 29, 2029

28 more

Vitrakvi8 patentsOct 21, 2029 AliqopaOct 22, 2029 CiproApr 27, 2030 StivargaJun 2, 2030 Nubeqa3 patentsOct 27, 2030 Stivarga2 patentsFeb 16, 2031 Aliqopa2 patentsMar 29, 2032 StivargaJul 9, 2032 Bayer Aspirin4 patentsSep 29, 2032 NubeqaMar 25, 2033 KerendiaAug 26, 2033 Adempas3 patentsFeb 18, 2034 CiproJul 1, 2035 KerendiaJul 29, 2035 HyrnuoOct 10, 2035 Vitrakvi4 patentsNov 16, 2035 Nubeqa3 patentsJan 28, 2036 LynkuetMay 18, 2036 VitrakviAug 15, 2036 Vitrakvi7 patentsApr 4, 2037 CiproNov 12, 2037 NubeqaFeb 27, 2038 CiproNov 27, 2038 Lynkuet3 patentsMar 13, 2039 NubeqaJul 2, 2040 LotriminMay 26, 2042 NubeqaJun 17, 2042 LynkuetMay 14, 2045

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Cardiovascular(6 drugs)

—

2

3

2

—

Cardiovascular(6 drugs)

Hematology(5 drugs)

1

1

1

1

1

Hematology(5 drugs)

Immunology(3 drugs)

—

—

3

—

—

Immunology(3 drugs)

Infectious Disease(2 drugs)

—

1

—

1

—

Infectious Disease(2 drugs)

Metabolic & Endocrine(2 drugs)

1

—

1

—

—

Metabolic & Endocrine(2 drugs)

Nephrology(8 drugs)

2

—

3

2

1

Nephrology(8 drugs)

Neurology(4 drugs)

1

—

1

2

1

Neurology(4 drugs)

Oncology(26 drugs)

7

14

8

2

2

Oncology(26 drugs)

Ophthalmology(3 drugs)

1

—

2

—

—

Ophthalmology(3 drugs)

Rare Disease(4 drugs)

3

—

1

—

—

Rare Disease(4 drugs)

Respiratory(2 drugs)

—

—

2

—

—

Respiratory(2 drugs)

Unknown / Other(10 drugs)

5

—

1

4

1

Unknown / Other(10 drugs)

Regulatory

Regulatory Timeline

20081 event

FDAJul 3

Eovist — EOVIST

Application NDA022090 (NDA)

20091 event

FDAMay 1

Cipro — CETRAXAL

Application NDA021918 (NDA)

20102 events

FDANov 19

Avelox — MOXEZA

Application NDA022428 (NDA)

FDAJun 17

Levitra — STAXYN

Application NDA200179 (NDA)

20121 event

FDASep 27

Stivarga — STIVARGA

Application NDA203085 (NDA)

20132 events

FDADec 18

Gadavist — GADAVIST

Application NDA201277 (NDA)

FDAOct 8

Adempas — ADEMPAS

Application NDA204819 (NDA)

20153 events

FDADec 10

Cipro — OTIPRIO

Application NDA207986 (NDA)

FDASep 4

Bayer Aspirin — DURLAZA

Application NDA200671 (NDA)

FDAApr 3

Avelox — MOXIFLOXACIN HYDROCHLORIDE

Application NDA205572 (NDA)

20171 event

FDASep 14

Aliqopa — ALIQOPA

Application NDA209936 (NDA)

20182 events

FDANov 26

Vitrakvi — VITRAKVI

Application NDA211710 (NDA)

FDANov 26

Vitrakvi — VITRAKVI

Application NDA210861 (NDA)

20191 event

FDAJul 30

Nubeqa — NUBEQA

Application NDA212099 (NDA)

20201 event

FDAAug 6

Lampit — LAMPIT

Application NDA213464 (NDA)

20212 events

FDAJul 9

Kerendia — KERENDIA

Application NDA215341 (NDA)

FDAFeb 26

Bayer Aspirin — VAZALORE

Application NDA203697 (NDA)

20253 events

FDANov 19

Hyrnuo — HYRNUO

Application NDA219972 (NDA)

FDAOct 24

Lynkuet — LYNKUET

Application NDA219469 (NDA)

FDASep 26

Lotrimin — CLOTIC

Application NDA217628 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)